Compare HODO & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HODO | PRPO |
|---|---|---|
| Founded | 2024 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.6M | 42.0M |
| IPO Year | 2024 | 2000 |
| Metric | HODO | PRPO |
|---|---|---|
| Price | $0.14 | $23.77 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 762.6K | 97.1K |
| Earning Date | 11-16-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.15 |
| EPS | ★ 0.05 | N/A |
| Revenue | $105.00 | ★ $24,049,000.00 |
| Revenue This Year | N/A | $233.72 |
| Revenue Next Year | N/A | $22.61 |
| P/E Ratio | $3.16 | ★ N/A |
| Revenue Growth | N/A | ★ 29.77 |
| 52 Week Low | $0.15 | $16.40 |
| 52 Week High | $2.52 | $33.63 |
| Indicator | HODO | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 18.56 | 42.16 |
| Support Level | N/A | $23.75 |
| Resistance Level | $0.20 | $24.95 |
| Average True Range (ATR) | 0.02 | 1.17 |
| MACD | 0.02 | -0.35 |
| Stochastic Oscillator | 5.82 | 28.23 |
Precipio Inc is a healthcare biotechnology company focused on cancer diagnostics. Its objective is to enhance diagnostic accuracy & accessibility while building a sustainable business model that supports ongoing innovation. The company operates Clinical Laboratory Improvement Amendments laboratories in both New Haven, Connecticut, & Omaha, Nebraska, providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. The company operates in a single segment, which includes two divisions: the Pathology Services Division & the Products Division. The Pathology Services provides specialized cancer diagnostic testing services. The pathology services division specializes in diagnostic testing focused mainly on hematologic cancers.